Ινστιτούτο Φαρμακευτικής Έρευνας & Τεχνολογίας Μ.Α.Ε.

Pharmacovigilance

Pharmacovigilance is a fundamental component of IFET S.A.’s pharmaceutical activities and encompasses the systematic and continuous monitoring of the safety of medicinal products throughout their entire life cycle. Its purpose is the timely identification, evaluation, understanding, and prevention of adverse drug reactions and other medicine-related risks, with the overarching objective of safeguarding Public Health.

 

The Company is fully compliant with the applicable European and national regulatory framework, as defined by:

  • Directive 2001/83/EC, as amended,
  • Regulation (EC) No 726/2004,
  • the Good Pharmacovigilance Practices (GVP) Guidelines of the European Medicines Agency (EMA), and
  • the relevant decisions and guidelines issued by the National Organization for Medicines.

 

Within this framework, the Company maintains a structured pharmacovigilance system, which includes the collection and evaluation of adverse reaction reports, the management of safety signals, the submission of required reports to the competent authorities, and the continuous assurance of compliance with regulatory requirements. Through the systematic implementation of pharmacovigilance procedures, as well as ongoing staff training, the Company actively contributes to ensuring the rational and safe use of medicinal products.

τel.: 213 2002 464, 213 2002 531
e-mail: safety@ifet.gr